Brought to you by 
Merck KGAA markets Novartis' Starlix to treat diabetes
01 Feb 2001
Executive Summary
Merck KGAA will co-promote and co-market Novartis' Starlix (nateglinide) in Europe, and specific African, Southeast Asian, and Latin American countries to treat Type II diabetes. The agreement will remain in place for as long as the drug is under patent.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Marketing
- Co-Promotion
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck KGAA markets Novartis' Starlix to treat diabetes
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice